Carna Biosciences, Inc. Logo

Carna Biosciences, Inc.

Develops kinase inhibitor drugs for oncology/autoimmune diseases & offers discovery support services.

4572 | T

Overview

Corporate Details

ISIN(s):
JP3220550002
LEI:
Country:
Japan
Address:
神戸市中央区港島南町一丁目5番5号
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

Carna Biosciences, Inc. is a clinical-stage biopharmaceutical company founded in 2003, specializing in the discovery and development of innovative kinase inhibitor drugs. The company focuses on creating small molecule therapies to address unmet medical needs in oncology, autoimmune diseases, and neurodegenerative disorders. Carna Biosciences operates a dual business model: advancing its proprietary drug pipeline for out-licensing and providing comprehensive drug discovery support services. These services include the manufacturing of kinase proteins, as well as offering profiling, screening, and assay development to support pharmaceutical and biotechnology research globally. The company leverages its deep expertise in kinase biology to develop novel therapeutic candidates.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-11 07:45
Registration Form
訂正有価証券届出書(組込方式)
Japanese 347.4 KB
2025-09-12 08:46
Registration Form
訂正有価証券届出書(組込方式)
Japanese 325.6 KB
2025-08-07 02:46
Registration Form
訂正有価証券届出書(組込方式)
Japanese 243.9 KB
2025-08-07 02:45
Registration Form
訂正有価証券届出書(組込方式)
Japanese 244.0 KB
2025-08-07 02:43
Interim Report
確認書
Japanese 8.8 KB
2025-08-07 02:42
Interim Report
半期報告書-第23期(2025/01/01-2025/12/31)
Japanese 358.3 KB
2025-07-11 08:47
Registration Form
有価証券届出書(組込方式)
Japanese 393.6 KB
2025-07-11 08:46
Registration Form
有価証券届出書(組込方式)
Japanese 393.6 KB
2025-07-11 08:45
Registration Form
有価証券届出書(組込方式)
Japanese 392.8 KB
2025-03-28 02:41
Regulatory News Service
臨時報告書
Japanese 28.5 KB
2025-03-26 02:11
Governance Information
内部統制報告書-第22期(2024/01/01-2024/12/31)
Japanese 24.5 KB
2025-03-26 02:10
Registration Form
確認書
Japanese 8.7 KB
2025-03-26 02:08
Annual Report
有価証券報告書-第22期(2024/01/01-2024/12/31)
Japanese 1.3 MB
2024-09-25 08:39
Share Issue/Capital Change
臨時報告書
Japanese 122.5 KB
2024-08-08 02:51
Report Publication Announcement
確認書
Japanese 8.7 KB

Automate Your Workflow. Get a real-time feed of all Carna Biosciences, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Carna Biosciences, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Carna Biosciences, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

VALIRX PLC Logo
Advancing oncology & women's health therapeutics and offering preclinical research services.
United Kingdom
VAL
VALUE GOLF Inc. Logo
A golf services hub offering reservations, solo player bookings, e-commerce, lessons, and tours.
Japan
3931
Value HR Co., Ltd. Logo
Offers a health management platform and consulting for corporate health insurance societies in Japan.
Japan
6078
Global OTA for curated tours & experiences, focusing on travel to and from Japan.
Japan
7048
A South Korean travel company offering global tour packages, flights, hotels, and corporate travel.
South Korea
094850
Virax Biolabs Group Ltd Logo
Specializes in T-cell immunity tests and diagnostics for profiling viral disease responses.
United States of America
VRAX
VisionSys AI Inc Logo
Develops AI-powered brain-computer interfaces for the healthcare and biotech sectors.
United States of America
VSA
Vivesto Logo
Develops and licenses novel cancer therapies for humans and animals using proprietary drug delivery.
Sweden
VIVE
Vor Biopharma Inc. Logo
Clinical-stage biotech developing next-gen medicines that target the root cause of autoimmune disease.
United States of America
VOR
Voronoi, Inc. Logo
Develops selective kinase inhibitors and targeted protein degraders for precision oncology.
South Korea
310210

Talk to a Data Expert

Have a question? We'll get back to you promptly.